TES treatment significantly reduced the ability of BM (7%) and spleen (6%) M-MDSCs to gain CD11c compared with cytokine alone (Fig. 3B, p < 0.05) whereas TES-treated, tumor-derived M-MDSC remained unable to gain CD11c expression (<1%). The gene discussed is ITGAX; the disease is neoplasm.